What to know about Medicare’s new hemp pilot program that drug safety groups are challenging in court

Published



Eligible medicare beneficiaries at participating healthcare providers will soon be able to purchase $500 worth of hemp-derived products annually for medical purposes.

Under a new Centers for Medicare and Medicaid Services pilot program that begins on Wednesday, participating healthcare providers can offer their eligible patients hemp-derived CBD and THC products for symptom control with no out-of-pocket cost to the patient.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.